Vol. 44 (1): 215-218, March – Abril, 2018
doi: 10.1590/S1677-5538.IBJU.2018.02.03
DIFFERENCE OF OPINION
Fernando G. Almeida 1, 2, Luciano Teixeira Silva 2
1 Departamento de Disfunções Urinárias, Urologia Feminina e Urodinâmica, 2 Departamento de Urologia, Universidade Federal de São Paulo, UNIFESP, Escola Paulista de Medicina, São Paulo, SP, Brasil
Keywords: Lasers; Therapeutics; Prostatic Hyperplasia; Transurethral Resection of Prostate
Benign prostate enlargement (BPE) is a highly prevalent pathology (1). The main consequence of BPE is Bladder Outlet Obstruction (BOO). Patients with BOO may be bothered by voiding lower urinary tract symptoms (LUTS). Those men with BOO and significant LUTS which did not respond to clinical approaches may be candidate to surgical procedures.
In patients with prostate volume inferior to 80-100 grams, monopolar transurethral resection of prostate (TURP) has been considered the gold standard for decades. The American Urological Association (AUA) considered TURP as standard treatment for BPH (2) and The European Urological Association considered TURP “the treatment of choice” for prostates sized 30 to 80 cm3 (3).
